Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RENB
- Price
- 1.24
- Stock movement down
- -0.35 (-2.69%)
- Company name
- Renovaro Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 292.36M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 152.19%
- 3 year return
- -14.42%
- 5 year return
- -18.77%
- 10 year return
- -
Last updated: 2025-09-30
DIVIDENDS
RENB does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.80 |
| Daily high | 13.54 |
| Daily low | 12.14 |
| Daily Volume | 297K |
| All-time high | 125.50 |
| 1y analyst estimate | - |
| Beta | 0.53 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 13 Nov 2025 |
Downside potential
Loading...
Downside potential data
| RENB | S&P500 | |
| Current price drop from All-time high | -99.01% | -0.29% |
| Highest price drop | -99.87% | -19.00% |
| Date of highest drop | 22 Sep 2025 | 8 Apr 2025 |
| Avg drop from high | -59.77% | -2.76% |
| Avg time to new high | 59 days | 5 days |
| Max time to new high | 961 days | 89 days |
COMPANY DETAILS
Marketcap
292.36M
Marketcap category
Small-cap
Description
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
Employees
25
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner